Last reviewed · How we verify
Choroidal retinal neovascularization
Approved treatments
- Visudyne · Bausch Lomb Ireland
Visudyne selectively binds to neovascular tissue, which is then activated by light to induce a phototoxic reaction. - Visudyne · Bayer
- Lucentis · Santen Inc.
- BYOOVIZ · SAMSUNG BIOEPIS CO LTD
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Choroidal retinal neovascularization patent landscape — cliff calendar, originator estates, attackable patents
- Choroidal retinal neovascularization treatment landscape brief
- Choroidal retinal neovascularization treatment updates RSS
Frequently asked questions about Choroidal retinal neovascularization
What drugs treat Choroidal retinal neovascularization?
Tracked treatments include Visudyne, Lucentis, BYOOVIZ.
What is the treatment for Choroidal retinal neovascularization?
Standard treatment for Choroidal retinal neovascularization includes Visudyne, Lucentis, BYOOVIZ. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Choroidal retinal neovascularization patent cliff · Choroidal retinal neovascularization CI report
- Treatment: Visudyne · Bausch Lomb Ireland
- Treatment: Visudyne · Bayer
- Treatment: Lucentis · Santen Inc.
- Treatment: BYOOVIZ · SAMSUNG BIOEPIS CO LTD
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing